Cited by 26Gastrointestinal motility and disordersDiabetes Treatment and ManagementRegulation of Appetite and Obesity

Effects of glucagon‐like peptide‐1 and sympathetic stimulation on gastric accommodation in humans1

Open access
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Nickander, K. K., Baxter, K. L. +1 more·2007·Neurogastroenterology & Motility

Abstract

Abstract In humans, glucagon‐like peptide‐1 (GLP‐1) delays gastric emptying by inhibiting vagal activity and also increases gastric volumes, by unclear mechanisms. Because GLP‐1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, we assessed the effects of a GLP‐1 agonist and yohimbine, an α2‐adrenergic antagonist, on gastric volumes in humans. In this double‐blind study, 32 healthy volunteers were randomized to placebo, a GLP‐1 agonist, yohimbine or GLP‐1 and yohimbine. Gastric volumes (fasting predrug and postdrug, and postprandial postdrug) were measured by 99m Tc single photon emission computed tomography imaging. Plasma catecholamines and haemodynamic parameters were assessed. Compared with placebo, GLP‐1 increased (P = 0.03) but yohimbine did not affect fasting gastric volume. However, GLP‐1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP‐1 alone [postprandial volume change = 542 ± 29 mL (mean ± SEM, placebo), 605 ± 31 mL (GLP‐1), 652 ± 54 mL (yohimbine) and 810 ± 37 mL (GLP‐1 and yohimbine)]. Plasma noradrenaline and dihydroxyphenylglycol concentrations were higher for yohimbine vs placebo and for GLP‐1 and yohimbine vs GLP‐1. Yohimbine stimulates central sympathetic activity and in combination with GLP‐1, augments postprandial accommodation in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2982.2007.00923.x

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 58 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Nickander, K. K., Baxter, K. L., & Zinsmeister, A. R.
Affiliations
Mayo Clinic (US)
Corresponding author
Bharucha, A. E.
Venue
Neurogastroenterology & Motility
Publisher
Wiley
Published
2007-04-02
Volume
19
Issue
9
Pages
716-723
ISSN
  • 1350-1925 (ISSN-L)
  • 1365-2982
OpenAlex
W2004876197
Cited by
26
References
58
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2014: 2 · 2013: 2 · 2012: 3
FWCI
1.50
Type
journal article
Language
en
Open access
Locations
  • Neurogastroenterology & Motility (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Mayo Clinic
  • National Institutes of Health
  • U.S. Public Health Service
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK-068254, P01DK068055)
  • National Center for Research Resources (RR-00585, M01RR000585)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, yohimbine, gastric accommodation, gastric volume, postprandial gastric emptying, sympathetic nervous system, norepinephrine, plasma catecholamines, vagal inhibition, intestinal motility
MeSH terms
Adrenergic alpha-Antagonists, Adult, Catecholamines, Double-Blind Method, Female, Humans, Male, Stomach, Sympathetic Nervous System, Yohimbine, Tomography, Emission-Computed, Single-Photon, Postprandial Period, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review